FDA warning letters
A warning letter is FDA's formal notice that a company broke the law, usually found during an inspection. The company has 15 working days to reply. Letters that go unanswered lead to seizures, import bans or court orders.
19 letters match. Newest first.
-
DrugsPeak Performance Peptides
Peak Performance Peptides sold unapproved injectable peptide drugs, including semaglutide and retatrutide, without FDA approval.
High risk -
DrugsRoyal Peptides LLC
FDA warned Royal Peptides LLC that seven peptide products sold on its website are unapproved new drugs.
High risk -
DrugsNuScience Peptides LLC
FDA warned NuScience Peptides that it sells unapproved injectable peptide drugs, including GLP-1 and tesamorelin products, on its website.
High risk -
DrugsPeptide Partners LLC
Peptide Partners LLC sold seven unapproved injectable peptide drugs online with disease-treatment claims, FDA says.
High risk -
DrugsTXP Innovations LLC dba Tex Peptides
FDA warned Dallas peptide seller TXP Innovations (Tex Peptides) that its website sells unapproved injectable drugs, including semaglutide and tirzepatide.
High risk -
DrugsGram Peptides
Gram Peptides sold unapproved injectable peptide drugs and bacteriostatic water online as new drugs, FDA says.
High risk -
DrugsPrime Sciences
Prime Sciences sells injectable peptide drugs and BAC water online without FDA approval, FDA says.
High risk -
DrugsGenoGenix LLC
FDA warns GenoGenix over insanitary sterile compounding, endotoxin-contaminated NAD+, and unapproved drugs.
High risk -
DrugsDarmerica, LLC
FDA warns Darmerica over manufacturing-quality violations and mislabeled drug ingredients, including retatrutide.
High risk -
DrugsAmazing Meds
FDA warned online seller Amazing Meds over unapproved compounded retatrutide and a misleading "same as Ozempic/Wegovy" semaglutide claim.
High risk -
DrugsGenLabMeds
GenLabMeds offered compounded retatrutide, semaglutide and tirzepatide online as unapproved, misbranded drugs with false or misleading claims.
High risk -
DrugsMedClub by Dr. Jenn
FDA warns MedClub by Dr. Jenn over unapproved compounded retatrutide and misleading semaglutide claims on its website.
High risk -
DrugsGLP-1 Solution
GLP-1 Solution sells unapproved compounded retatrutide online and misleadingly compares semaglutide and tirzepatide to FDA-approved brand drugs.
High risk -
DrugsASN-LABS
ASN-LABS marketed unapproved compounded retatrutide and misleading semaglutide claims online, FDA says.
High risk -
DrugsEA WORKS Limited Liability Company dba Trust Labs
FDA warned Trust Labs it sold unapproved compounded retatrutide and made false FDA-approval claims for semaglutide and tirzepatide online.
High risk -
DrugsPrime Vitality, Inc. dba Prime Peptides
FDA warned Prime Peptides that its website sells Semaglutide and Retatrutide as unapproved new drugs for weight loss and diabetes.
High risk -
DrugsSwisschems
Swisschems sells Semaglutide and Retatrutide as unapproved new drugs despite research-chemical labeling.
High risk -
DrugsXcel Research LLC
FDA warned Xcel Research for selling unapproved peptide drugs online with human-use claims.
High risk -
DrugsSummit Research Peptides
FDA warned Summit Research Peptides for selling unapproved semaglutide, retatrutide, cagrilintide, tirzepatide, and mazdutide with drug claims.
High risk